Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection

Aim This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs. Methods AE data were extracted from the Australian Paediatric ITB Research Group national database, to include the first...

Full description

Saved in:
Bibliographic Details
Published in:Journal of paediatrics and child health 2021-02, Vol.57 (2), p.258-262
Main Authors: Tyack, Louise, Copeland, Lisa, McCartney, Lynn, Waugh, Mary‐Clare
Format: Article
Language:English
Subjects:
adverse event
Australia
Baclofen - adverse effects
Child
Data Collection
Humans
Infusion Pumps, Implantable
Injections, Spinal
intrathecal baclofen
Muscle Relaxants, Central - adverse effects
Muscle Spasticity - drug therapy
paediatric rehabilitation
paediatrics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs. Methods AE data were extracted from the Australian Paediatric ITB Research Group national database, to include the first 5 years of data collection. Raw data were collated and analysed descriptively. Results Data were collected for 40 patients. Forty‐seven AEs in 23 patients were reported. Ten (25%) patients required surgical intervention related to their AE. Five patients (12.5%) required pump removal. The most frequent ITB‐related AEs were catheter dysfunction (24%), drug overdose, withdrawal or sensitivity (19%), seromas and haematomas (15%) and infections (13%). Conclusions The AE rate for ITB therapy is high and needs to be considered when counselling patients regarding ITB as a therapeutic option.
ISSN:1034-4810
1440-1754
DOI:10.1111/jpc.15194